De Novo device
INVOcell Intravaginal Culture System
Invo Bioscience · Culture, Intravaginal, Assisted Reproduction (OYO, Class II) · First FDA decision Nov 2, 2015, newest Jun 22, 2023Infertility
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
De Novo pathway
Device trials
5
Naming "INVOcell"
MAUDE reports
0
Brand "INVOcell", since 2015
PubMed studies
13
Mentioning "INVOcell"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing INVOcell Intravaginal Culture System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
K222932 · Decided Jun 22, 2023 · 269 days after receipt
Device type: Culture, Intravaginal, Assisted Reproduction (OYO) · Obstetrics & Gynecology
- INVOcellNew device typeDe Novo
DEN150008 · Decided Nov 2, 2015 · 252 days after receipt
Device type: Culture, Intravaginal, Assisted Reproduction (OYO) · Obstetrics & Gynecology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "INVOcell", any status and sponsor, newest update first.
- Comparing Intra-vaginal Culture of Embryos to In-vitro Culture of Embryos With Minimal StimulationTerminated
University of California, San FranciscoAcademic, hospital or other
NCT02802176 · 39 participants · Start Oct 2016 · Primary completion Apr 20, 2022
Device: INVOcell device · For: Infertility
Sites: San Francisco, California
INVO Bioscience, Inc.Not on our public-company list
NCT05189405 · 450 participants (planned) · Start Oct 12, 2021 · Primary completion Feb 28, 2022
Device: INVOcell IVC · For: Infertility
Sites: Raleigh, North Carolina; Greenville, South Carolina; Bedford, Texas · 4 sites in all
INVO Bioscience, Inc.Not on our public-company list
NCT04644380 · 31 participants · Start Dec 2, 2020 · Primary completion Dec 11, 2020
Device: INVOcell · For: Infertility
Sites: Homewood, Alabama
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "INVOcell", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OYO
1 reports: 1 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "INVOcell"[tiab]. The summary above synthesizes these.
- Vaginal culture for IVF allows two mothers to carry the same pregnancy: Is more always better?
Babcock Gilbert S, Polotsky AJ · Case Rep Womens Health · 2019Editorial
- Randomized prospective study comparing conventional In Vitro Fertilization technique to Intravaginal Culture with the INVOCELLࡊ device for 3 and 5 days.
Aguiar LF, Cunha GDSPD, Cordido KAAT, et al. · JBRA Assist Reprod · 2023Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Intravaginal embryo culture: a successful alternative to standard IVF that may improve access to care.
Cooper AR · Curr Opin Obstet Gynecol · 2022Review
- Intravaginal culture using INVOCELL: Is it a viable treatment option for infertility?
Babayev E, Jain T · F S Rep · 2021Editorial
- Real-world experience with intravaginal culture using INVOCELL: an alternative model for infertility treatment.
Jellerette-Nolan T, Cooper AR, Doody KJ, et al. · F S Rep · 2021
- INVO procedure: minimally invasive IVF as an alternative treatment option for infertile couples.
Lucena E, Saa AM, Navarro DE, et al. · ScientificWorldJournal · 2012
- Simulated gestation: The social and ethical implications of in vivo fertilisation technology.
Lee JY, Villalba A, Fernández-Jimeno N · Bioethics · 2025
- Comparison of Treatment Outcomes among Sibling Oocytes Using Different Culture Systems-Conventional IVF versus INVOcell Device-And Evaluation of INVOcell User Satisfaction: The INVOcIVF Study.
Yang Mohsin WS, Abdullah Chue NS, Abdul Hamid F, et al. · Int J Environ Res Public Health · 2022
- Introduction of the method of intravaginal culture (IVC), through the device INVOCell routine laboratory RHA in Brazil.
Coelho F, Aguiar LF, Cunha GSP, et al. · JBRA Assist Reprod · 2022
- Comparing blastocyst quality and live birth rates of intravaginal culture using INVOcellࡊ to traditional in vitro incubation in a randomized open-label prospective controlled trial.
Doody KJ, Broome EJ, Doody KM · J Assist Reprod Genet · 2016Randomized Controlled Trial
- A systematic review of reproductive technologies for shared conception in same-sex female couples.
Dubois B, Naveed H, Nietsch KS, et al. · Fertil Steril · 2024Systematic Review
- A pilot study to evaluate a device for the intravaginal culture of embryos.
Mitri F, Esfandiari N, Coogan-Prewer J, et al. · Reprod Biomed Online · 2015Randomized Controlled Trial, Research Support, Non-U.S. Gov't
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.